Amgen Inc. — Wall Street Analyst Estimates & Price Targets

AMGN

NASDAQHealthcareDrug Manufacturers - GeneralCIK 0000318154amgen.comAbout AMGN

Last close · Oct 16, 2026432.49−1.54 (−0.35%)

Market cap$233.8B

18 firms' latest targets, last 90 days: median $412.50 ($230.00–$500.00), 5% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 18 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-13	Guggenheim	$378.00	$388.00	▼ 3%	-9%	-13%
2026-10-12	BMO Capital	$415.00	$450.00	▼ 8%	+0%	-4%
2026-10-12	Wells Fargo	$430.00	$435.00	▼ 1%	+4%	-1%
2026-10-08	RBC Capital	$430.00	$400.00	▲ 7%	+6%	-1%
2026-10-08	Cantor Fitzgerald	$440.00	$400.00	▲ 10%	+7%	+2%
2026-10-07	Truist	$380.00	$325.00	▲ 17%	-8%	-12%
2026-09-28	Scotiabank	$500.00	$450.00	▲ 11%	+20%	+16%
2026-09-23	Jefferies	$410.00	$350.00	▲ 17%	+0%	-5%
2026-09-17	UBS	$430.00	$420.00	▲ 2%	+14%	-1%
2026-08-20	Piper Sandler	$457.00	$427.00	▲ 7%	+3%	+6%
2026-08-19	Morgan Stanley	$362.00	$333.00	▲ 9%	-18%	-16%
2026-08-19	Argus Research	$460.00	—	—	+5%	+6%
2026-08-18	Mizuho Securities	$352.00	$303.00	▲ 16%	-16%	-19%
2026-08-14	Barclays	$380.00	$360.00	▲ 6%	-9%	-12%
2026-08-06	Bernstein	$345.00	$335.00	▲ 3%	-15%	-20%
2026-08-05	Oppenheimer	$450.00	$400.00	▲ 13%	+15%	+4%
2026-08-05	Baird	$230.00	—	—	-41%	-47%
2026-08-05	Canaccord Genuity	$384.00	$366.00	▲ 5%	-2%	-11%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$28.2B	+7%	$12.49	+3%	est. $28.1B+0%	est. $18.56	18
2024reported	$33.4B	+19%	$7.56	-39%	est. $33.2B+1%	est. $19.61	20
2025reported	$36.8B	+10%	$14.23	+88%	est. $36.4B+1%	est. $21.32	20
2026	$39.0B	+6%	$23.04	+8%	$38.6B–$39.6B	$22.57–$23.32	24
2027	$40.4B	+4%	$24.51	+6%	$39.2B–$42.0B	$22.85–$26.07	23
2028	$41.8B	+3%	$25.90	+6%	$38.1B–$47.2B	$21.03–$29.24	27
2029	$43.4B	+4%	$27.69	+7%	$41.9B–$45.8B	$26.44–$29.73	13
2030	$45.3B	+4%	$29.63	+7%	$43.7B–$47.8B	$28.30–$31.81	13

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$412.50median target, 5% below the last close

Firms with a target · last 90 days: 18
Lowest – highest target: $230.00 – $500.00
Current grades of 24 firms: positive / neutral / negative: 9 / 13 / 2
Upgrades / downgrades · 12 months: 0 / 4
Consensus revenue growth · next 3 FY: +4% a year

Current grades

each firm's latest · 24 firms

As of	Firm	Grade
2026-10-13	Guggenheim	“Neutral”
2026-10-12	Wells Fargo	“Equal Weight”
2026-10-12	BMO Capital	“Market Perform”
2026-10-09	UBS	“Buy”
2026-10-08	Cantor Fitzgerald	“Neutral”
2026-10-08	RBC Capital	“Outperform”
2026-10-07	Truist	“Hold”
2026-10-07	Morgan Stanley	“Equal Weight”
2026-09-29	Scotiabank	“Sector Outperform”
2026-09-10	HSBC	“Hold”

14 more

2026-08-20	Piper Sandler	“Overweight”
2026-08-19	Argus Research	“Buy”
2026-08-18	Mizuho	“Neutral”
2026-08-14	Barclays	“Equal Weight”
2026-08-07	Citigroup	“Neutral”
2026-08-06	Bernstein	“Market Perform”
2026-08-05	TD Cowen	“Buy”
2026-08-05	Goldman Sachs	“Buy”
2026-08-05	Bank of America	“Underperform”
2026-08-05	Canaccord Genuity	“Hold”
2026-08-05	Baird	“Underperform”
2026-08-05	Oppenheimer	“Outperform”
2026-02-12	Freedom Capital Markets	“Hold”
2026-02-04	Leerink Partners	“Outperform”

Grade changes

last 24 months · 4

Date	Firm	Grade
2026-09-10	HSBC	“Buy” → “Hold” downgrade
2026-09-08	BMO Capital	“Outperform” → “Market Perform” downgrade
2026-02-12	Freedom Capital Markets	“Buy” → “Hold” downgrade
2026-01-20	Bernstein	“Outperform” → “Market Perform” downgrade

52 older than 24 months

2024-10-14	Truist	“Buy” → “Hold” downgrade
2024-08-07	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2024-05-03	William Blair	“Market Perform” → “Outperform” upgrade
2024-05-03	Barclays	“Underweight” → “Equal Weight” upgrade
2023-12-21	Daiwa Capital	“Neutral” → “Buy” upgrade
2023-12-19	BMO Capital	“Market Perform” → “Outperform” upgrade
2023-12-12	RBC Capital	“Sector Perform” → “Outperform” upgrade
2023-11-02	Truist	“Hold” → “Buy” upgrade
2023-10-11	Leerink Partners	“Market Perform” → “Outperform” upgrade
2023-03-13	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2022-10-31	Barclays	“Equal Weight” → “Underweight” downgrade
2022-10-11	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2022-01-05	Bank of America	“Buy” → “Neutral” downgrade
2021-09-23	Daiwa Capital	“Outperform” → “Neutral” downgrade
2021-09-07	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2021-04-28	Atlantic Equities	“Neutral” → “Underweight” downgrade
2020-10-26	Raymond James	“Market Perform” → “Outperform” upgrade
2020-10-12	Truist	“Buy” → “Hold” downgrade
2020-10-09	Bernstein	“Outperform” → “Market Perform” downgrade
2020-03-30	Raymond James	“Market Perform” → “Outperform” upgrade
2020-03-13	CFRA	“Hold” → “Buy” upgrade
2020-03-05	Bank of America	“Neutral” → “Buy” upgrade
2020-01-31	Baird	“Neutral” → “Underperform” downgrade
2020-01-21	Evercore ISI	“In Line” → “Outperform” upgrade
2019-11-05	Cantor Fitzgerald	“Neutral” → “Overweight” upgrade
2019-08-19	Mizuho	“Buy” → “Neutral” downgrade
2019-05-23	Citigroup	“Neutral” → “Buy” upgrade
2019-01-28	Evercore ISI	“Outperform” → “In Line” downgrade
2018-05-05	Argus	“Hold” → “Buy” upgrade
2018-02-05	Atlantic Equities	“Overweight” → “Neutral” downgrade
2018-01-23	Argus	“Hold” → “Buy” upgrade
2017-11-01	Argus	“Buy” → “Hold” downgrade
2017-07-26	BMO Capital	“Outperform” → “Market Perform” downgrade
2017-04-05	Jefferies	“Buy” → “Hold” downgrade
2017-02-01	Bank of America	“Neutral” → “Buy” upgrade
2015-12-15	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2015-09-07	UBS	“Neutral” → “Buy” upgrade
2015-07-09	UBS	“Buy” → “Neutral” downgrade
2015-01-05	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2014-10-29	Nomura	“Neutral” → “Buy” upgrade
2013-08-26	Piper Sandler	“Neutral” → “Overweight” upgrade
2013-05-01	Goldman Sachs	“Neutral” → “Buy” upgrade
2013-04-24	Piper Sandler	“Overweight” → “Neutral” downgrade
2013-02-11	William Blair	“Outperform” → “Market Perform” downgrade
2013-01-25	Argus Research	“Hold” → “Buy” upgrade
2013-01-22	Credit Suisse	“Outperform” → “Neutral” downgrade
2012-10-22	Deutsche Bank	“Hold” → “Buy” upgrade
2012-09-12	Baird	“Outperform” → “Neutral” downgrade
2012-09-10	UBS	“Neutral” → “Buy” upgrade
2012-07-27	Piper Sandler	“Neutral” → “Overweight” upgrade
2012-07-25	Credit Suisse	“Neutral” → “Outperform” upgrade
2012-02-09	Oppenheimer	“Outperform” → “Perform” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.